ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AMYT Amryt Pharma Plc

143.00
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 143.00 151.00 170.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Amryt Pharma Share Discussion Threads

Showing 2451 to 2472 of 7375 messages
Chat Pages: Latest  103  102  101  100  99  98  97  96  95  94  93  92  Older
DateSubjectAuthorDiscuss
06/3/2018
14:01
It's worth remembering that Episalvan (AP101) has a better chance of success with it's phase III trials than Zorblisa, since Zorblisa was only partially successful with it's phase II trials. Makes you wonder why Amicus paid so much for Scioderm in the first place!



Regarding Episalvan's competitors: FCX-007 (gene theraphy) is at an early stage (phase I/II)



Berg's cream is still in phase I



Castle Creek's ointment is the "closest" competitor to Episalvan. It's ointment is in phase III

papillon
06/3/2018
13:13
There was also a small "gap up" this morning, diamondstar, as the MM's opened at 19.50p, slightly up from yesterday's 19.075p close. It wouldn't surprise me to see the share price fall back sometime this week to close that small "gap up". We shall see!
papillon
06/3/2018
12:52
The share price has broken out of a downtrend on my log chart, diamondstar, going back to the placing RNS of 21st September so perhaps my comment on the chart being still bearish was harsh. I suppose one could say the chart is neither bullish, nor bearish, but just awaiting news.

Regarding the placing, whilst as you say it was oversubscribed, nobody back in September 2017 who took part in the placing could be certain that the EASE trial would be deemed successful.

By holding, or buying AMYT, one is taking a gamble on the outcome of the EASE phase III trial. Whilst I'm willing to take that gamble, others might not.

papillon
06/3/2018
12:25
Hi Paps, My instinct tells me that the share price should hopefully overcome this 20.25 resistance level over the coming days. My simplistic rationale is this.... the drop over the past few weeks from 20p to a low of 17.30p has likely flushed out the weak holders of Amryt shares, and also the pessimists. What we are largely left with now are shareholders who believe in Amryt as a company, and who are less likely to sell. With the upcoming interim results, people will want to position themselves to gain from the results - therefore, I believe share demand will actually exceed supply.
Of course, there are some short term traders as seen today, who bought @ 17-18p, and are now selling at resistance level. But I still think Amryt shares are a good buy @ 20p. Remember that the 15 million euro capital raise was highly oversubscribed.
This analysis is not quantitative or based on any charts, but simply my gut feeling. We shall see over the next few days what happens till the announcement on 15th March.

diamondstar1
06/3/2018
12:17
Depends on what's announced on the 15th March, pottermagic. The RNS's issued so far this year have only had a small effect on the AMYT share price so far. The share price has basically traded so far this year between support @ circa 17.25p and resistance at circa 20.25p.
Only good news regarding the EASE interim trial results will propel the AMYT share price above resistance at circa 27p. Investors buy on good news and the prospect of good news. The news issued so far this year has not been considered good enough to have a marked effect on the share price

Firstly we are not 100% certain the update on 15th March is about the EASE interim trial results and even if it is we are not 100% certain that it will be good news that's issued.

Really good (or bad news) will blow my chart out of the water as I've posted many times before. The chart will only give a guide to that news if there has been a leak. I very much doubt that news has leaked and I hope it hasn't because the AMYT chart is currently bearish. I can only assume that potential investors are unsure of the EASE interim trial results. At the moment it looks like they will wait until the update is issued on 15th March before taking a position. Looking at the chart THAT'S WHAT I HOPE!!

papillon
06/3/2018
11:10
The share price is also up against the upper Bollinger Band and the 200 day EMA. Further resistance to break @ 20.25p.
papillon
06/3/2018
11:07
It's currently up against resistance @ 20.25p, diamondstar (my chart showed resistance circa 20.25p). We'll see if it holds. If it breaks that resistance the next resistance level is @ circa 27p.
papillon
06/3/2018
10:12
Nice little uplift this morning.....we seem to be coming out of sleep mode these days, lots happening! 😃
greendragon777
06/3/2018
08:44
The following RNS doesn't seem to appear on this site:


6 March 2018
AIM: AMYT
ESM: AYP

Amryt Pharma plc
("Amryt" or the "Company")

Senior Management Appointment

Amryt, a biopharmaceutical company focused on treatments for rare and orphan diseases, is pleased to announce the appointment of Jordi Casals as the Company's Head of Europe.

Jordi will be responsible for leading and further developing Amryt's European operations, including product launches. His initial focus is on the continuing sales growth of the Company's commercial asset, Lojuxta, a treatment for adult patients with Homozygous Familial Hypercholesterolaemia.

Jordi has over 20 years' experience in the pharmaceutical and biotech industry. Most recently, he worked for Aegerion Pharmaceuticals as a Consultant, managing its commercial operations in the Iberia region. Before that, he worked for eight years at Alexion Pharmaceuticals, latterly as VP Commercial Operations Western Europe. He has also held sales and marketing roles at Grifols S.A., the European multinational pharmaceutical, and Otsuka Pharmaceutical Europe, the Japan-based pharmaceutical company.

Jordi holds an MBA from UPC University, Barcelona, together with a Pharmacy Degree from Barcelona University.

Dr. Joe Wiley, Chief Executive Officer, commented:

"I am pleased to welcome Jordi to our senior management team as the Company's Head of Europe. His significant commercial experience of European markets will help us to drive and further develop Amryt's growth across this key region."


Enquiries:

Amryt Pharma plc

+353 (1) 518 0200

Joe Wiley, CEO

Rory Nealon, CFO/COO

bazworth
06/3/2018
08:44
It would be nice to reach the 24-25p level again before the EASE Ph III results, to fill the ‘Gap Down’ we had when the 15 million euro was raised. I know Paps - this is optimistic thinking!
diamondstar1
06/3/2018
08:39
Wow, I didn’t expect a 10% rise so early in the morning. This must be in anticipation of the EASE results, rather than RNS with another regional expansion.
diamondstar1
06/3/2018
07:29
Thank you papillon, Sounds good news this morning! Roll on 15th of March
goku28
06/3/2018
07:16
Two x RNS this morning!

Sounding very good!

bazworth
06/3/2018
00:24
Expect some resistance around the 20p mark in the coming days. If that doesn't hold then circa 27p is the next resistance level.
papillon
05/3/2018
23:59
Goku28. Go to:



Select your market. The UK. You can access their free charts that show support and resistance levels. You have to register. Input AMYT in the "symbol search" and it will show the updated AMYT 18 month chart showing support and resistance levels. The charts are computer generated and will show a computer generated trend. It costs money to access all the features (not worth it, IMO, though you can get a free trial), but you can access the Medium Term Chart (18 months) for free, which has extra features, like RSI, moving averages and volume balance) by clicking on the icon. It wont be up to date though (currently showing Friday's chart).

The AMYT chart shows support at 17.10p and resistance at 20.30p and 27p. They tie in with my figures. I also have support at circa 14p.

papillon
05/3/2018
18:38
I don't think the AMYT share price is likely to rocket over the next few days, diamondstar, even if it would be nice if it did, though it could rise further. I expect the Bollinger Bands to tighten over the coming week, or so, prior to the update on 15th March.


free stock charts from uk.advfn.com

PS. The AMYT share price is likely to rise above the 27p resistance on good news being issued on the 15th March. Thereafter the share price is likely to rise significantly higher in the following weeks. Of course the share price is likely to fall below the 14p support on bad phase III results. Fingers crossed we get good news!!

papillon
05/3/2018
18:02
Bronxville
Posts: 116
Off Topic
Opinion: No Opinion
Price: 19.075
RE: Timing of Release EASE InterimsToday 16:38 Jury's still out on management,we will see soon.
Afterall ALL of the big investors here are still in the red.
I'll keep my powder dry until the 15th.

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

I don't know if the management is currently doing a good job, or not, Bronxville. There is no doubt that Cathal Friel & Joe Willey did an excellent job in extracting 24p a share from investors in the first placing (giving AMYT an initial sky high Mkt Cap of around £50m)!! They could get blood out of a stone!! LOL. With the benefit of hindsight those investors overpaid (though some privileged investors bought at a significant discount to that 24p at the placing). AMYT was never worth 24p a share back in the summer of 2016 (bearing in mind that valuation depended on a treatment for an orphan drug that wouldn't be first to the market and about to enter phase III) consequently the share price rather quickly subsequently fell to circa 14p (giving a Mkt Cap of around £30m). Only the subsequent good news of the EIB loan and the revenue generating Lojuxta licensing deal gave credence to that 24p placing price (and initial £50m Mkt Cap) and caused a sharp recovery in the share price and stopped the share price falling even lower than 14p.

Unfortunately the EASE interim results will also not prove whether the AMYT BoD is doing a good job, or not, Bronxville, because the BoD wont know how the trials are going; the results are out of their hands currently. They should be in the dark (I hope they are!!) as to how the trial is going just like we are.

ATB Bronxville from papillon aka "the idiot". LOL

papillon
05/3/2018
15:31
Looks like I spoke to soon, as there was a relatively large sale of 59,469 shares at 18.67 p recently. Even with a rising share price and upcoming interims, there are pessimists out there. Looking at the pattern of share buying and selling, it looks like there is a pattern... for example, I believe there is someone accumulating shares - this person appears to buy 125,000 shares during each transaction (like today). I could be wrong, and there could be separate buyers, but my theory is there is just 1 buyer purchasing 125,000 shares each time.
diamondstar1
05/3/2018
14:14
Having said what I did above, I accept that the Amryt Senior Management will likely have a bit of time (few days to 1 week) to put their heads together, to discuss the message they want to convey in their press release. There is also a possibility Pottermagic that some few very Senior Amryt members might have access to 'Flash Results' a couple of weeks beforehand... to give them a bit of head start, in preparing for the press release.
diamondstar1
05/3/2018
14:04
Hi Pottermagic, you have put down some good points. However, my feeling it that Amryt Senior Management will not have that much time (i.e. several weeks) to ponder over the results. I believe that the DSMB Charter will empower the study decision making to the 3 (or perhaps more) DSMB members, as External Experts. If the results are borderline (Scenario 1) as you have mentioned, then I believe the DSMB will make the decision either 1) Continue study or 2) Increase sample size. If the results are negative i.e, Scenario 2, with no divergence between active an placebo, then they have to terminate study. Meanwhile, if clearly positive (Scenario 3), they will have to continue study, without any sample size increase. The longer they wait to announce the results, the larger the risk exists for the interim results to be leaked. Hence, I personally believe the announcement of the interim results should be soon after the Amryt Senior Management find out the results.
diamondstar1
05/3/2018
13:41
The share price is set to rocket over the next few days. I tried to put in orders between £3-5k in Amryt shares. Supply has absolutely dried up; could not execute. Only £1k could be purchased, for 19.25p!!
diamondstar1
05/3/2018
13:26
We'll have to set our alarm clocks early that day Paps! :-)
greendragon777
Chat Pages: Latest  103  102  101  100  99  98  97  96  95  94  93  92  Older

Your Recent History

Delayed Upgrade Clock